BridgeBio Pharma participated in a series B round for its subsidiary Eidos Therapeutics, which is working on treatments for a family of rare genetic diseases known as ATTR.
US-based biopharmaceutical firm Eidos Therapeutics raised $64m in a series B round yesterday backed by its parent company, biotechnology conglomerate BridgeBio Pharma.
The round was led by RA Capital Management and also included Janus Henderson, Viking Global Investors, Aisling Capital, Perceptive Advisors, Cormorant Asset Management and Amzak Health Investors.
Eidos Therapeutics is working on therapies for a family of rare genetic diseases caused by transthyretin amyloidosis (ATTR), characterised by a build-up of the amyloid protein in the nervous system, heart,…
